Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
A Tanaka, S Sadahiro, T Suzuki… - Oncology …, 2018 - spandidos-publications.com
Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with
refractory metastatic colorectal cancer. However, it is unclear which patients may derive a …
refractory metastatic colorectal cancer. However, it is unclear which patients may derive a …
Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison
T Masuishi, H Taniguchi, S Hamauchi, A Komori… - Clinical Colorectal …, 2017 - Elsevier
Background Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients
with refractory metastatic colorectal cancer. However, it is unclear which drug should be …
with refractory metastatic colorectal cancer. However, it is unclear which drug should be …
A real-world comparison of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer in the United States
Background: Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the
United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals …
United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals …
Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies
T Sueda, D Sakai, T Kudo, T Sugiura… - Anticancer …, 2016 - ar.iiarjournals.org
Background: Regorafenib and TAS-102 are novel antitumor agents for patients with
metastatic colorectal cancer (mCRC) whose disease has progressed after standard …
metastatic colorectal cancer (mCRC) whose disease has progressed after standard …
[HTML][HTML] Maximising clinical benefit with adequate patient management beyond the second line in mCRC
G Argiles, D Arnold, G Prager, AF Sobrero… - ESMO open, 2019 - Elsevier
New therapeutic options for refractory metastatic colorectal cancer (mCRC) include
trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic …
trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic …
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the …
T Moriwaki, S Fukuoka, T Masuishi… - International Journal of …, 2020 - Springer
Background Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a
later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all …
later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all …
Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a …
T Moriwaki, S Fukuoka, H Taniguchi… - The …, 2018 - academic.oup.com
Background This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD)
in patients with metastatic colorectal cancer (mCRC) who are refractory to standard …
in patients with metastatic colorectal cancer (mCRC) who are refractory to standard …
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study in Japan
M Ogata, M Kotaka, T Ogata, Y Hatachi, H Yasui… - PLoS …, 2020 - journals.plos.org
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic
colorectal cancer patients previously treated with standard chemotherapies; therefore, we …
colorectal cancer patients previously treated with standard chemotherapies; therefore, we …
Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institution
Background The combination drug TAS-102 is a novel oral nucleoside antitumor agent
containing trifluridine and tipiracil hydrochloride, which prevents the degradation of …
containing trifluridine and tipiracil hydrochloride, which prevents the degradation of …
A systematic review and network meta‐analysis of regorafenib and TAS‐102 in refractory metastatic colorectal cancer
Background Regorafenib at different dosing strategies and TAS‐102 are treatment options
for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative …
for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative …